EASL 2019 Conference bulletinRead our 2019 International Liver Congress bulletin. Margaret Hellard presenting at The International Liver Congress. Image: @AnnetteGaudino and @TAGTeam_TweetsFinance and funding$51 billion price tag for eliminating hepatitis C by 2030. Markus Cornberg presenting at The International Liver Congress. Image: EASL Education @EASLeduPangenotypic regimensPangenotypic hepatitis C drug combinations curing almost all people who complete treatment, real-world studies show. infohep news Hepatitis C elimination Hepatitis elimination by 2030 in doubt as countries fail to scale up diagnosis and treatment Keith Alcorn / 24 April 2019 Most countries will struggle to eliminate hepatitis C by 2030 due to lack of investment and political will, missing an internationally agreed target set by the World Health Organization, The International Liver Congress ... NAFLD Emricasan misses study endpoint for improving portal hypertension in people with NASH Liz Highleyman / 24 April 2019 The experimental caspase inhibitor emricasan did not meet the statistical threshold for improvement of portal hypertension in people with non-alcoholic steatohepatitis (NASH), but it did appear to have some benefit for those at ... Gastrointestinal problems, nausea and vomiting Faecal transplants improve encephalopathy in people with advanced liver disease Liz Highleyman / 24 April 2019 Faecal microbiota transplantation (FMT), which helps restore a healthy mix of bacteria in the gut, can help reverse brain function impairment in people with liver failure, according to a report at the International ... NAFLD NAFLD a rising cause of liver disease in people with HIV Liz Highleyman / 23 April 2019 Now that hepatitis C can be successfully treated, non-alcoholic fatty liver disease (NAFLD) is becoming an increasingly important cause of serious liver problems and liver-related death among people living with HIV in the ... Antiviral therapy Tenofovir may lower the risk of liver cancer more than entecavir Liz Highleyman / 18 April 2019 People with hepatitis B who were treated with tenofovir disoproxil fumarate (TDF; Viread) were less likely to develop hepatocellular carcinoma (HCC) than those treated with entecavir (Baraclude) in a large observational study, according ... Antiviral therapy Core protein inhibitor shows promising activity against hepatitis B Liz Highleyman / 16 April 2019 An experimental hepatitis B virus (HBV) core protein inhibitor led to greater reductions in HBV viral load and residual HBV genetic material when added to nucleoside/nucleotide analogues, which could lead to a functional ... Monitoring response to treatment Simplified monitoring for hepatitis C is as effective as standard monitoring Keith Alcorn / 16 April 2019 People who had a simplified monitoring schedule of hepatitis C viral load tests at the beginning of treatment and 12 weeks after completing treatment were just as likely to be cured as ... Hepatitis D Bulevirtide is a potential cure for hepatitis B and D Liz Highleyman / 16 April 2019 Bulevirtide, formerly known as Myrcludex B, led to suppression of hepatitis delta virus (HDV) and a functional cure of hepatitis B virus (HBV) in some people with both viruses when combined with pegylated ... NAFLD Obeticholic acid improves liver fibrosis in people with NASH Liz Highleyman / 12 April 2019 Obeticholic acid (Ocaliva) led to a significant improvement in liver fibrosis related to non-alcoholic steatohepatitis (NASH), offering a potential future option for an increasingly common liver disease with no good current therapies, researchers ... Pan-genotypic regimens Pangenotypic hepatitis C drug combinations curing almost all people who complete treatment, real-world studies show Keith Alcorn / 12 April 2019 Once-daily combination pills that can treat all genotypes of hepatitis C infection are curing almost everyone who completes a course of treatment, and drop-out rates during treatment are low, large 'real-world' cohort ... View more > Editors' picks from other sources NAFLD Experts warn of fatty liver disease 'epidemic' in young people The Guardian / 12 April 2019 Access to medicines & diagnostics Global hepatitis response gains ground – More action needed to achieve universal health coverage targets World Health Organization / 12 April 2019 NAFLD Second-generation thiazolidinedione, MSDC-0602K may significantly improve liver enzymes, fibrosis, and glycaemic markers with minimal adverse events, according to a Phase 2b study EASL / 12 April 2019 Treatment for previous non-responders & relapsers ‘Real-world’ studies in Germany and the USA confirm high rates of sustained virological response with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in individuals with chronic HCV infection failing DAAs EASL / 12 April 2019 View more > Other pages in this section Latest news All the news Conference news Email bulletin archive